Fingolimod
Trovati 2 articoli
- Relapsing multiple sclerosis: Gilenia shows benefits
- The Phase II trial data showed that Fingolimod ( FTY720; Gilenia ) taken once-daily during the initial six months of treatment for relapsing multiple sclerosis reduced the rate of inflammatory disease activity - as measured by magnetic resonance imaging ( MRI ) - by up to 80% and cut clinical rel... (Leggi Articolo)
- Relapsing multiple sclerosis: Fingolimod produces a sustained efficacy over 18 months
- Data from the extension of a Phase II study to 18 months support the significant effects of FTY720 ( Fingolimod; Gileania ), a novel once-daily oral compound in development for treatment of relapsing-remitting multiple sclerosis. The data, presented at the American Association of Neurology ( A... (Leggi Articolo)
